EMD Group (EMD Serono Research Institute (Billerica))
45A Middlesex Turnpike
Billerica
Massachusetts
01821
United States
Tel: 978-294-1100
Website: http://www.come2emd.com
About EMD Group (EMD Serono Research Institute (Billerica))
Overview At the EMD Group, around 40,000 people in more than 60 countries develop pharmaceutical and chemical innovations. In 2010 the company generated total revenues of EUR 9.3 billion. It is the world’s oldest pharmaceutical and chemical company with roots dating back to 1668. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.From the start of industrial production in 1827, to initial research on liquid crystals more than 100 years ago, up to our entry into targeted cancer therapy with the launch of Erbitux®, many milestones in our history provide strong evidence of the pioneering spirit of the people at EMD. From innovative drugs to treat multiple sclerosis, cold remedies to new technologies for energy-efficient light sources our pioneering spirit in research and our experience enable us to develop products that improve quality of life.
Since going public in 1995, the company’s operating activities are under the umbrella of Merck KGaA Darmstadt, Germany.
Career Opportunities Do you want to continue to experiment, analyze and break new ground? Welcome to EMD. When it comes to innovations, you will find us in the front ranks. And the breadth of our ceative research is far-reaching: from medicines, through opportunities in bio-research and bio-production, all the way to liquid crystals for LCDs. Enough latitude, in other words, to make your passion a true calling. Bring us entrepreneurial flair, plenty of team spirit and a total commitment to delivering the best possible results for our customers, and you’ll go far. You’ll enjoy all the interest and exposure of working in multidisciplinary, international teams. Depending on your field of expertise, you may even have the chance to develop across business sectors and functions.
To find out where you could go in an organization that’s part of Merck KGaA, Darmstadt, Germany, a global force in chemicals and pharmaceuticals with operations in more than countries and revenues of €9.3 billion in 2010, please visit come2emd.com.
EMD Group is an Equal Opportunity Employer.
Products: Pharmaceuticals EMD Serono is the largest division of the EMD Group and discovers, develops, manufactures and commercializes innovative prescription drugs and therapies for high unmet medical needs. The focus lies in specialist therapeutic areas such as oncology, multiple sclerosis and infertility. Through their targeted effect, these medicines help patients to live a longer and better life. Many consumers around the world trust a wide range of well-known brands that EMD develops, manufactures and markets for the OTC (over-thecounter) pharmaceutical sector.
Chemicals Our broad range of specialty chemicals are used in technologically sophisticated applications ranging from liquid crystal, to effect pigments and cosmetic ingredients. The EMD Group is the global leader in the liquid crystals market. Liquid crystals are used throughout the world, in LCD TVs, monitors, tablet computers, notebooks, mobile phones, and digital cameras. In addition to the display materials business, the Performance Materials division focuses on materials for energy-saving lighting using LEDs (light-emitting diodes) and OLEDs (organic LEDs). Pigments for the plastics, printing and coatings industries as well as for cosmetic applications are an important part of the Performance Materials portfolio. Moreover, the division is the market leader for pearl-luster effect pigments.
With the EMD Millipore division, the EMD Group is a leading life science company, which offers products, applications and solutions for protein research and cell biology as well as for the manufacture of chemical-based and biopharmaceutical drugs. The portfolio comprises products for life science research such as assays, biomarkers and targeted solutions, as well as bioprocessing, lab water purification and filtration. Additionally, the division supplies specialty chemicals mainly to regulated markets, for example the pharmaceutical, cosmetics and food industries. Analytical and scientific laboratories use the reagents and test kits supplied by the division. The EMD Millipore portfolio comprises more than 40,000 products and processes. Thank you in advance! I am looking forward to hearing from you.
36 articles about EMD Group (EMD Serono Research Institute (Billerica))
-
EMD Serono, Inc. (Billerica) Founding Donor of Newly Launched MGH Multiple Sclerosis Discovery Forum
4/17/2012
-
EMD Serono, Inc. (Billerica) and Fast Forward, LLC Commit $3 Million for Multiple Sclerosis
10/19/2011
-
EMD Serono, Inc. (Billerica) Honored as a 2011 Working Mother 100 Best Company
9/15/2011
-
EMD Serono, Inc. (Billerica) Committed to Transparency in Interactions with Healthcare Professionals and Organizations
6/23/2011
-
EMD Serono, Inc. (Billerica)’s Commitment to Advance Multiple Sclerosis Care and Research Underscored by Data to Be Presented at AAN 2011 Meeting
4/8/2011
-
EMD Serono, Inc. Receives CEO Cancer Gold StandardTM Accreditation
3/24/2011
-
CIGNA Corporation and EMD Serono Team to Fight Multiple Sclerosis Under First Outcomes-Based Specialty Medication Contract
3/17/2011
-
CIGNA Corporation and EMD Serono Team to Fight Multiple Sclerosis Under First Outcomes-Based Specialty Medication Contract
3/16/2011
-
Merck KGaA's EMD Serono, Inc. (Billerica)'s MS Drug Cladribine Rejected by FDA
3/2/2011
-
EMD Serono, Inc. (Billerica) Holds Grand Opening Ceremony for New State-of-the-Art Research Center in Billerica, MA
2/10/2011
-
EMD Serono, Inc. Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relapsing Forms of Multiple Sclerosis
11/29/2010
-
EMD Serono, Inc., Merck KGaA Says FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of MS
7/28/2010
-
Merck KGaA Resumes Vaccine Trials in Lung Cancer; Stimuvax Trials on Breast Cancer Remain Suspended
6/17/2010
-
EMD Serono, Inc. and Fast Forward, LLC Announce First Results of Their Collaboration to Advance Drug Development in Multiple Sclerosis
5/5/2010
-
EMD Serono, Inc.'s New Data Supporting Cladribine Tablets as a Potential New Therapeutic Option Presented at the 62nd American Academy of Neurology Annual Meeting
4/16/2010
-
EMD Serono, Inc. Launches the EMD Serono Specialty Digest(TM) at the 22nd Annual Meeting of the Academy of Managed Care Pharmacy
4/9/2010
-
EMD Serono, Inc. Names Lisa Costantino as Chief Financial Officer for US Organization
2/17/2010
-
EMD Serono, Inc.: Two-Year Results From CLARITY Study with Cladribine Tablets in Multiple Sclerosis Published in The New England Journal of Medicine
1/21/2010
-
EMD Serono, Inc. and Nationally Ranked US Hospital Announce Collaboration in Basic and Clinical Research in Multiple Sclerosis
12/16/2009
-
EMD Serono, Inc. President and CEO Fereydoun Firouz Honored by Massachusetts Biotechnology Council with its 2009 Innovative Leadership Award
4/14/2009